SLC5A1 and type 2 diabetes mellitus: The SGLT1 inhibition component appears to add to the benefits of SGLT2i in that sotagliflozin reduced nonfatal and fatal stroke as well as nonfatal and fatal MI in patients with T2DM by >30% (Bhatt, Szarek, Pitt, et al., 2021; Bhatt, Szarek, Steg, et al., 2021).